Latest News about REGN
Recent news which mentions REGN
US Stocks Rise Despite China's Trade Fears, Palantir Defies Gravity, Gold Rallies Further: What's Driving Markets Tuesday?
February 04, 2025
From Benzinga
Regeneron Pharma Q4 Earnings Crush Estimates, Initiates Dividend And Additional Stock Buyback Program
February 04, 2025
From Benzinga
Earnings Scheduled For February 4, 2025
February 04, 2025
From Benzinga
9 Health Care Stocks With Whale Alerts In Today's Session
January 28, 2025
From Benzinga
Looking Into Regeneron Pharmaceuticals's Recent Short Interest
January 24, 2025
Tickers
REGN
From Benzinga
From Benzinga
From Benzinga
Obesity Treatments, M&A Activity To Take Center Stage During Upcoming JPM Healthcare Conference
January 09, 2025
From Benzinga
What Analysts Are Saying About Regeneron Pharmaceuticals Stock
January 08, 2025
Tickers
REGN
From Benzinga
Tickers
REGN
From Motley Fool
From Benzinga
Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More
December 22, 2024
From Benzinga
Regeneron's Best-Selling Eye Drug Eylea's Higher Dose Formulation Meets Primary Goal In Another Form Of Retinal Disease Study
December 17, 2024
From Benzinga
Stocks Slip As Strong November Retail Sales Raise Concerns Over 2025 Fed Rate Cuts
December 17, 2024
From Benzinga
What 25 Analyst Ratings Have To Say About Regeneron Pharmaceuticals
December 17, 2024
Tickers
REGN
From Benzinga
Jim Cramer: This Energy Stock Is A 'Winner,' But Navitas Semiconductor Is 'Losing A Lot Of Money'
December 04, 2024
From Benzinga
Peering Into Regeneron Pharmaceuticals's Recent Short Interest
November 18, 2024
Tickers
REGN
From Benzinga
FDA To Revisit Regeneron/Sanofi's Dupixent For Rare Skin Disease
November 15, 2024
From Benzinga
28 Analysts Have This To Say About Regeneron Pharmaceuticals
November 14, 2024
Tickers
REGN
From Benzinga
2 Top Growth Stocks to Buy on the Dip
November 14, 2024
From Motley Fool
Regeneron/Sanofi's Dupixent Approval Signals Major Treatment Breakthrough For Smokers' Lung Disease
November 13, 2024
From Benzinga
Assessing Regeneron Pharmaceuticals's Performance Against Competitors In Biotechnology Industry
November 06, 2024
From Benzinga
Is It Time to Buy October's Worst-Performing Nasdaq Stocks?
November 06, 2024
From Motley Fool
Upstream Bio Is New On NASDAQ, Can Potentially Beat AstraZeneca's Asthma Drug On Efficacy, Analysts Say
November 05, 2024
From Benzinga
This Is What Whales Are Betting On Regeneron Pharmaceuticals
November 04, 2024
Tickers
REGN
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.